Massive Sell-off: $800 Billion Vanished from US Biotech in One Day

Kymera Therapeutics Inc. (NASDAQ: KYMR) closed at $108.12 on June 26, down 7.16% on the day. Volume jumped to 3.74 million shares, and market capitalization fell by about $590 million to $8.89 billion. The sell-off followed a regulatory filing showing director Bruce Booth sold roughly $44 million of stock between June 23 and 25, raising concerns over insider unloading. Despite this, Wall Street analysts remain bullish, maintaining a Buy consensus and an average price target near $118. In its first quarter, Kymera beat both revenue and earnings expectations, reinforcing its growth narrative.

Kymera is a clinical-stage biotech developing oral immune and oncology therapies via targeted protein degradation. Its pipeline features the IRAK4 degrader KT-474 and the atopic dermatitis candidate KT-621, among other assets. Recent milestones—including early completion of enrollment in the KT-621 Phase 2b BROADEN2 trial and initial clinical data for KT-474—along with partnerships with Sanofi and Gilead, have positioned the company for meaningful clinical and commercial catalysts in 2026.